Gram-negative coccobacilli are a group of bacteria whose shape falls between a sphere and a rod, and whose double-layered cell envelope gives them remarkable tools for surviving hostile environments, including the human body and the hospital. The group includes some of the most medically significant pathogens on the planet: Acinetobacter baumannii, Haemophilus influenzae, Brucella species, Francisella tularensis, and Bordetella pertussis, among others. What makes them collectively worrisome is not just the diseases they cause but the structural and genetic features they share that make them difficult to treat with conventional antibiotics.
The Outer Membrane and Why It Matters
All gram-negative bacteria share a defining architectural feature: an outer membrane sitting on top of a thin cell wall, with a gel-like space (the periplasm) sandwiched in between. That outer membrane is not just a passive barrier. It is studded with proteins that control what enters and exits the cell, and its outer face is coated with lipopolysaccharide (LPS), a molecule that plays a dual role as structural scaffold and immune trigger. In most gram-negative species, LPS is a potent activator of the innate immune system. When immune cells detect it, they launch an inflammatory response meant to contain the infection.
Some coccobacilli, however, have evolved LPS variants that the immune system barely recognizes. Francisella tularensis, the agent of tularemia, produces an LPS that fails to bind key immune-sensing molecules such as LPS-binding protein. Research has shown that F. tularensis LPS does not compete with LPS from other bacteria for binding to these recognition proteins, suggesting that the molecule is essentially invisible to a critical arm of innate defense.1PubMed Central. Basis for the failure of Francisella tularensis lipopolysaccharide to prime human polymorphonuclear leukocytes This stealth quality helps explain why tularemia can be so aggressive even though inhaling only a handful of bacteria is enough to start an infection.
Acinetobacter baumannii takes a different approach. Its LPS is highly inflammatory, and the bacterium actually uses that inflammation to its advantage in some settings. Because the resulting tissue damage loosens iron stores and disrupts host barriers, the inflammatory chaos can paradoxically benefit a pathogen that thrives in nutrient-rich, damaged environments.2PubMed Central. Acinetobacter Metabolism in Infection and Antimicrobial Resistance In short, even within the coccobacillus category, the outer membrane is not a one-size-fits-all tool. Each species has tuned its surface chemistry for its own survival strategy.
How These Bacteria Feed and Breathe
Metabolically, gram-negative coccobacilli range from highly self-sufficient to surprisingly dependent on host nutrients. Acinetobacter baumannii is an obligate aerobe, meaning it requires oxygen, but it can burn through a wide variety of carbon sources to generate energy.2PubMed Central. Acinetobacter Metabolism in Infection and Antimicrobial Resistance That metabolic flexibility is one reason it persists so well in hospitals, where it can colonize surfaces, equipment, and patients with different nutritional landscapes.
Haemophilus influenzae, by contrast, is famously picky. It cannot make its own NAD, a molecule essential for cellular energy reactions, because it lacks the entire set of enzymes needed for that synthesis. In the lab, researchers supply NAD (historically called “factor V”) directly; in the body, the bacterium must scavenge it from damaged tissues or nearby cells.3PubMed. Is a NAD pyrophosphatase activity necessary for Haemophilus influenzae type b multiplication in the blood stream? This dependence shapes where H. influenzae can live: it favors the respiratory tract, where mucosal cells release NAD precursors, and it rarely causes infections at sites far from that supply.
Iron Acquisition
Iron is critical for nearly all bacteria, but the human body keeps free iron at vanishingly low levels as a deliberate defense. Gram-negative coccobacilli have evolved elaborate systems to steal it. Many species produce siderophores, small molecules that latch onto iron with extraordinary strength and shuttle it back through specialized outer-membrane channels.4PubMed Central. Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics
A. baumannii goes further, employing multiple strategies simultaneously. It can lyse red blood cells to harvest heme, deploy siderophores, and release outer-membrane vesicles that grab iron from the surrounding environment.5PubMed Central. Iron Acquisition Mechanisms and Their Role in the Virulence of Acinetobacter baumannii Having several backup systems means that knocking out one iron-uptake route does not necessarily starve the bacterium. That redundancy is a recurring theme in A. baumannii biology, and it has practical consequences for drug development: targeting just one pathway may not be enough.
Getting a Foothold on Host Tissue
Before a bacterium can cause disease, it has to stick to something. For many gram-negative coccobacilli, that first handshake with host tissue depends on surface structures like pili and outer-membrane proteins. In A. baumannii, a protein called OmpA is particularly important. OmpA binds directly to fibronectin and integrins on human epithelial cells, and when researchers knock out the gene for OmpA, adhesion to those cells drops sharply.6Trends in Microbiology. Gram-Negative Coccobacilli: Structure, Metabolism, and Resistance Mechanisms This makes OmpA both a virulence factor and a potential drug target.
Other coccobacilli rely on released material rather than fixed surface structures. Aggregatibacter actinomycetemcomitans, a major player in aggressive periodontitis, sheds adhesins packaged in vesicles that coat nearby surfaces and prepare them for colonization.7PubMed. Virulence Factors of the Periodontopathogen Actinobacillus actinomycetemcomitans Meanwhile, resistant strains of A. baumannii ramp up production of CsuA/B, a pilus protein with strong adhesive properties, alongside their resistance machinery, giving them a survival advantage on both biological and non-biological surfaces such as plastic catheters.8Journal of Proteome Research. Quantitative Profiling and Identification of Outer Membrane Proteins of β-Lactam Resistant Strain of Acinetobacter baumannii
Hiding Inside Host Cells
Some gram-negative coccobacilli do not just stick to surfaces; they invade host cells and set up shop inside them. Francisella tularensis is a textbook intracellular pathogen. After being taken up by macrophages (the immune cells tasked with eating invaders), it briefly tolerates the harsh conditions of an acidified compartment, then ruptures that compartment’s membrane and escapes into the cell’s cytoplasm, where it replicates freely.9PubMed Central. Exploitation of host cell biology and evasion of immunity by francisella tularensis The bacterium essentially hijacks the very cells meant to kill it.
Brucella melitensis, which causes brucellosis, follows a similar intracellular strategy but relies on a broader genetic toolkit. A recent genomic screen identified 374 genes essential for B. melitensis survival inside macrophages, spanning functions from membrane stability to carbon metabolism to regulation of the citric acid cycle.10PubMed Central. Comprehensive genomic identification of essential genes required for Brucella melitensis intracellular survival during macrophage infection Deleting any of several tested genes reduced the bacterium’s ability to survive inside those cells. The sheer number of genes involved underscores how deeply intracellular life is woven into Brucella‘s biology.
Beta-Lactam Resistance
Beta-lactam antibiotics, which include penicillins and cephalosporins, work by disrupting the enzymes bacteria use to build their cell walls. Gram-negative coccobacilli resist them through two broad strategies: destroying the drug or altering the drug’s target.
Haemophilus influenzae illustrates both approaches. Many strains produce beta-lactamase enzymes that chew up ampicillin before it can act. But a growing fraction of resistant strains are beta-lactamase negative, meaning they resist ampicillin not by destroying it but by carrying mutations in the gene ftsI, which encodes a protein the drug normally binds. Those mutations reshape the target enough that the antibiotic no longer fits.11PubMed Central. Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin A large meta-analysis confirmed that specific clusters of substitutions in this protein are strongly associated with resistance to both ampicillin and cefotaxime, a third-generation cephalosporin.12PubMed Central. Revisiting mutational resistance to ampicillin and cefotaxime in Haemophilus influenzae These target-mutation strains are clinically tricky because standard lab tests for beta-lactamase come back negative, potentially misleading clinicians into thinking the bacterium is susceptible.
Carbapenem Resistance in Acinetobacter
Carbapenems are often treated as antibiotics of last resort for serious gram-negative infections. In A. baumannii, resistance to carbapenems has become alarmingly common, driven primarily by a family of enzymes called oxacillinases (OXA-type carbapenemases). Three classes in particular, OXA-23, OXA-40 (also called OXA-24), and OXA-58, have been identified worldwide. When researchers introduced genes for these enzymes into susceptible A. baumannii strains, the bacteria gained intermediate to high levels of carbapenem resistance, and inactivating the OXA-40 gene in a naturally resistant strain reduced that resistance.13PubMed Central. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii
Surveillance data from Taiwan confirmed that strains carrying an OXA-24-like gene encoding the OXA-72 carbapenemase were frequently associated with high-level carbapenem resistance.14PubMed Central. Types and prevalence of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex in Northern Taiwan The problem compounds when these enzymes team up with efflux pumps, as discussed below: resistance genes and efflux pump overexpression in the same strain can push carbapenem resistance from intermediate to untreatable.
Efflux Pumps and Multidrug Resistance
If enzymatic destruction is one arm of resistance, efflux is the other. Efflux pumps are molecular machines embedded in the bacterial envelope that physically push antibiotics back out of the cell before they reach their targets. In Acinetobacter species, resistance-nodulation-division (RND) efflux pumps are major contributors to multidrug resistance, capable of expelling beta-lactams, fluoroquinolones, aminoglycosides, and other drug classes.15PubMed Central. Update on Multidrug Resistance Efflux Pumps in Acinetobacter spp.
One system, AdeIJK, appears to be universal across the genus Acinetobacter. Genomic and structural work has shown that AdeIJK (and its equivalent AdeXYZ in other species) is present in every Acinetobacter species examined, suggesting it is not just a resistance tool but a fundamental part of the cell’s housekeeping, involved in functions like membrane lipid balance.16PubMed Central. RND pumps across the genus Acinetobacter: AdeIJK is the universal efflux pump That dual role creates a dilemma for drug designers: you cannot simply knock out the pump without potentially killing beneficial functions the bacterium needs, which sounds useful until you realize the goal is not to kill the bacterium outright but to re-sensitize it to existing drugs, often in combination regimens.
Overexpression of the related AdeABC system has been directly linked to higher levels of carbapenem resistance when paired with OXA-type enzymes, creating a synergy between two distinct resistance mechanisms within a single cell.13PubMed Central. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii
Colistin Resistance and the Last Line of Defense
When carbapenems fail, clinicians often turn to colistin (polymyxin E), an old antibiotic with significant toxicity that had been shelved for decades before multidrug-resistant gram-negatives forced its revival. Colistin works by binding to the lipid A portion of LPS and disrupting the outer membrane. Resistance in A. baumannii arises when the bacterium chemically modifies its lipid A by adding phosphoethanolamine, which reduces colistin’s ability to bind.
This modification is controlled by a two-component signaling system called PmrAB. Specific point mutations in the pmrB gene lead to overexpression of a phosphoethanolamine transferase (PmrC), which then decorates lipid A with the phosphoethanolamine group.17PubMed Central. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system Analysis of colistin-resistant clinical isolates confirmed that amino acid substitutions at specific positions in PmrB are consistently associated with this lipid A modification.18Scientific Reports. Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin–sulbactam combination therapy When even colistin stops working, treatment options become extremely limited.
Biofilms and Hospital Persistence
Resistance genes and efflux pumps explain why antibiotics fail inside the body, but biofilms explain why these organisms are so hard to eliminate from the hospital environment. Biofilms are communities of bacteria encased in a self-produced matrix of sugars, proteins, lipids, and DNA. Inside a biofilm, bacteria are shielded from both antibiotics and disinfectants, and they shift into a slower-growing state that makes them inherently harder to kill.19PubMed Central. Acinetobacter baumannii Biofilm Formation and Its Role in Disease Pathogenesis: A Review
A. baumannii is prolific at forming biofilms on both medical devices and dry hospital surfaces. Pili assembled through a chaperone-usher system, along with exopolysaccharides, are visible structural components of these biofilms.20PubMed. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system The practical payoff for the bacterium is striking: biofilm-forming strains survived on dry surfaces for an average of 36 days, compared with just 15 days for strains that did not form biofilms.21PubMed. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces That difference of roughly three weeks means contaminated bed rails, ventilator tubing, or keyboards can harbor viable bacteria long after a patient has been discharged, seeding new infections.
Immune Evasion Beyond LPS
The stealth LPS of Francisella and the intracellular hiding tactics of Brucella are not the only ways coccobacilli dodge the immune system. Haemophilus influenzae secretes a protease (IgA1 protease) that cleaves immunoglobulin A, the antibody that patrols mucosal surfaces. The enzyme snips the antibody at a hinge region, separating the part that recognizes the bacterium from the part that recruits immune effectors. In some cases, the bacterium retains the recognition fragment on its surface, effectively wearing a disguise that masks its own antigens.22PubMed Central. Small-molecule inhibitors of Haemophilus influenzae IgA1 protease Researchers have recently identified small-molecule inhibitors of this protease with promising selectivity, opening a potential route to anti-virulence drugs that disarm the bacterium without directly killing it.
How Resistance Genes Spread
Gram-negative coccobacilli do not rely solely on random mutation to acquire resistance. They actively exchange genetic material through horizontal gene transfer, a process that can leapfrog resistance traits between strains and even between species. H. influenzae has been shown to acquire multidrug resistance through conjugative transfer of integrative conjugative elements (ICEs), mobile DNA segments that carry multiple resistance genes at once, as well as through natural transformation, in which the bacterium picks up free DNA from its environment, including resistance-conferring versions of chromosomal genes.23PubMed Central. Role of Horizontal Gene Transfer in the Development of Multidrug Resistance in Haemophilus influenzae
Moraxella catarrhalis provides another example. The BRO beta-lactamase gene responsible for ampicillin resistance in this species shows a random distribution across strain types, inconsistent with vertical inheritance. Laboratory experiments confirmed that the gene transfers readily between M. catarrhalis strains through natural transformation.24PubMed. Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: evidence for transformation-mediated horizontal transfer The upshot is that resistance does not stay confined to the strain that developed it; it radiates outward through bacterial communities, sometimes very quickly.
Diagnostic Pitfalls
Identifying gram-negative coccobacilli accurately is not as routine as it might sound. Their similar shapes and growth characteristics can confuse both traditional biochemical tests and newer automated platforms. A documented case involving Brucella melitensis showed that MALDI-TOF mass spectrometry, the gold-standard identification tool in many clinical labs, misidentified the pathogen as Ochrobactrum anthropi, a far less dangerous environmental organism.25PubMed Central. The Brief Case: Misidentification of Brucella melitensis as Ochrobactrum anthropi by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry A missed Brucella identification is not just a clerical error. Brucellosis requires a specific prolonged antibiotic regimen and, crucially, the organism poses a serious laboratory safety hazard. Handling live cultures outside a high-containment facility can infect lab workers through aerosols. When the instrument calls it Ochrobactrum, no safety alert is triggered, and staff may handle the culture on an open bench.
Emerging Therapeutics Targeting LPS Biosynthesis
With conventional antibiotics failing against extensively drug-resistant coccobacilli, researchers are exploring entirely new angles. One of the more creative approaches targets LpxC, an enzyme in the LPS biosynthesis pathway. In a mouse model, an LpxC inhibitor did not directly kill A. baumannii (the minimum inhibitory concentration exceeded 512 micrograms per milliliter), but it suppressed LPS-mediated activation of the immune receptor TLR4. The result was reduced inflammation, enhanced phagocytic killing by immune cells, and complete protection of mice from a lethal infection.26PubMed Central. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis In other words, the drug worked by changing the host-pathogen dynamic rather than by acting as a traditional antibiotic.
Building on that concept, newer programs have developed non-hydroxamate LpxC inhibitors using cell-based screening platforms that link colistin resistance to blockade of LPS synthesis.27ACS Infectious Diseases. Development of LpxC Inhibitors Based on the Mechanism of Action of Colistin in Acinetobacter baumannii A separate medicinal chemistry effort produced a series of potent LpxC inhibitors active against a wide range of gram-negative pathogens, including multidrug-resistant strains, with demonstrated efficacy in animal infection models.28PubMed Central. Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections None have reached clinical use yet, but LpxC inhibition represents one of the more advanced new strategies against bacteria that have outrun existing drugs.
Vaccines Built from Bacterial Vesicles
Prevention would obviously be preferable to treating infections that resist most antibiotics. One promising platform uses outer-membrane vesicles (OMVs), tiny blebs of outer membrane that bacteria naturally shed and that carry many of the same surface antigens the immune system needs to recognize. Licensed OMV-based vaccines already exist for Neisseria meningitidis serogroup B and Haemophilus influenzae type b.29PubMed Central. Outer Membrane Vesicle Vaccine Platforms Preclinical work is now exploring whether similar OMV-based approaches could protect against A. baumannii and other multidrug-resistant coccobacilli. The appeal is that OMVs present antigens in their native conformation, potentially training the immune system more realistically than purified protein vaccines. Genetic engineering and chemical conjugation techniques are extending the platform’s reach, allowing researchers to load OMVs with antigens from pathogens that do not naturally produce useful vesicles.